Nerve regeneration gene therapy - Oxford Biomedica
Alternative Names: Innurex; RARβ2 gene therapy - Oxford BioMedicaLatest Information Update: 09 Dec 2010
Price :
$50 *
At a glance
- Originator Oxford BioMedica
- Class Gene therapies
- Mechanism of Action Gene transference; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 28 Aug 2007 The nerve regeneration gene therapy is still in preclinical development for spinal cord injury in the UK
- 23 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Neurological Disorders pharmacodynamics section
- 09 Jun 2005 Preclinical data from a media release have been added to the Neurological disorders pharmacodynamics section